PROBIOTIX HEALTH PLC

Company number

13723211

Status

Active

Incorporation

2021-11-04

Last accounts made up

2024-12-31

Account category

GROUP

Primary SIC

86900

Hubs

UK Healthcare

Accounting basis

IFRS

Reporting scope

Consolidated (group)

Auditor

Gerald Edelman LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The financial statements have been prepared on the assumption that the Group is a going concern. When assessing the foreseeable future, the Directors have looked at the Cash forecast for the next 12 months from the date of this report, the cash at bank available as at the date of approval of this report and are satisfied that the Group should be able to cover its committed cost, and other administrative expenses, as well as its ongoing research and development expenditure.”

Subsidiaries

• Probiotix Limited · 100% held · United Kingdom · Health Foods
• Probiotix Health Denmark Aps · 100% held · Denmark · Health Foods

Significant events

• “Launch of two YourBiotix capsule products targeting cholesterol lowering (Cholicard) and general heart health support (Sofabiol) in Ukraine and Uzbekistan in partnership with DeutchPharm.”
• “Launch of line extension of a LPLDL containing YourBiotix stick product (Beifolac) by Eifron in Greece aimed at cholesterol lowering and complementing their already well-established brand (Bifolac) within probiotic supplements.”
• “Launch of YourBiotix LPLDL containing sticks in Denmark and China by Danish/Chinese brand Dancare.”
• “The commercial partnership with Seed Health led to expanded distribution across 4,000 Target stores in the USA and brand differentiation into irritable bowel syndrome and diarrhea, which significantly increased brand visibility and market penetration.”
• “Signing of an exclusive distribution agreement on sales of our bulk LPLDL® strain was concluded with Mexican distributor RAFF.”
• “The number of active sales projects in Europe and the USA enjoyed a step change, with a significant increase in active sales projects reaching a total of more than 30, including progressing several strategic projects with leading brands planning a late 2025 or early 2026 launch.”
• “Mr. Kasper Rønnenkamp Hoffensetz was hired as Sales Manager EMEA to expand commercial reach in Europe, Middle East, and Africa.”
• “Associate professor Mr. Hiva Alipour was hired part time as Head of Scientific Affairs.”
• “Associate professor Mrs. Fereshteh Dardmeh was hired part time as Head of Research & Development.”
• “Mr. Frederik Bruhn-Petersen was appointed non-executive director of the Company bringing complementary resources to the existing board competencies.”
• “On 19 February 2025 the company granted 9,050,000 options over the ordinary shares of 0.05p each in the company to Steen Andersen and certain other key employees of the company.”

Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers